The estimated Net Worth of Markus Sieger is at least $106 Tisíc dollars as of 20 April 2023. Markus Sieger owns over 59,881 units of Cyclo Therapeutics stock worth over $106,294 and over the last 4 years Markus sold CYTH stock worth over $0.
Sign up
Markus Sieger CYTH stock SEC Form 4 insiders trading
Markus has made over 4 trades of the Cyclo Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Markus bought 59,881 units of CYTH stock worth $42,516 on 20 April 2023.
The largest trade Markus's ever made was buying 59,881 units of Cyclo Therapeutics stock on 20 April 2023 worth over $42,516. On average, Markus trades about 4,494 units every 41 days since 2021. As of 20 April 2023 Markus still owns at least 161,051 units of Cyclo Therapeutics stock.
You can see the complete history of Markus Sieger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Markus Sieger's mailing address?
Markus's mailing address filed with the SEC is C/O CYCLO THERAPEUTICS, INC., 6714 NW 16TH STREET, SUITE B, GAINESVILLE, FL, 32653.
Insiders trading at Cyclo Therapeutics
Over the last 4 years, insiders at Cyclo Therapeutics have traded over $0 worth of Cyclo Therapeutics stock and bought 4,648,141 units worth $6,142,223 . The most active insiders traders include Holdings, Inc. Rafael, Shawn Cross a N Scott Fine. On average, Cyclo Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $78,661. The most recent stock trade was executed by Holdings, Inc. Rafael on 1 August 2023, trading 4,000,000 units of CYTH stock currently worth $5,000,000.
What does Cyclo Therapeutics do?
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
What does Cyclo Therapeutics's logo look like?
Complete history of Markus Sieger stock trades at Cyclo Therapeutics
Cyclo Therapeutics executives and stock owners
Cyclo Therapeutics executives and other stock owners filed with the SEC include:
-
N. Scott Fine,
CEO & Director -
Dr. Sharon H. Hrynkow Ph.D.,
Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Sr. VP of Medical Affairs -
Dr. Jeffrey L. Tate,
COO, Chief Quality Officer & Director -
Dr. Lise Lund Kjems M.D., Ph.D.,
Chief Medical Officer -
Lori McKenna Gorski,
Global Head of Patient Advocacy -
Michael Eric Lisjak,
Chief Regulatory Officer & Sr. VP of Bus. Devel. -
George L. Fails,
Exec. VP and Operations Mang. -
Joshua M. Fine,
CFO & Sec. -
C. E Strattan,
Founder & Director -
Randall M. Toig,
Director -
Shawn Cross,
Director -
Vivien Wong,
Director -
Holdings, Inc. Rafael,
10% owner -
Francis Patrick Ostronic,
Director -
William S Shanahan,
Director -
Michael Eric Lisjak,
Chief Regulatory Officer -
Sharon Hemond Hrynkow,
Chief Scientific Officer -
N Scott Fine,
Chief Executive Officer -
Joshua M Fine,
Chief Financial Officer -
Jeffrey Tate,
Chief Operating Officer -
Markus Sieger,
Director -
Ce Rick Strattan,
Director -
Lise Lund Kjems,
Chief Medical Officer -
William Conkling,
Director